0001437749-20-001950.txt : 20200206
0001437749-20-001950.hdr.sgml : 20200206
20200206204503
ACCESSION NUMBER: 0001437749-20-001950
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200204
FILED AS OF DATE: 20200206
DATE AS OF CHANGE: 20200206
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mathers James
CENTRAL INDEX KEY: 0001676166
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36362
FILM NUMBER: 20584340
MAIL ADDRESS:
STREET 1: C/O BIOLIFE SOLUTIONS
STREET 2: 3303 MONTE VILLA PARKWAY, SUITE 310
CITY: BOTHELL
STATE: WA
ZIP: 98021
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIOLIFE SOLUTIONS INC
CENTRAL INDEX KEY: 0000834365
STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
IRS NUMBER: 943076866
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3303 MONTE VILLA PARKWAY
STREET 2: SUITE 310
CITY: BOTHELL
STATE: WA
ZIP: 98021
BUSINESS PHONE: 4254011400
MAIL ADDRESS:
STREET 1: 3303 MONTE VILLA PARKWAY
STREET 2: SUITE 310
CITY: BOTHELL
STATE: WA
ZIP: 98021
FORMER COMPANY:
FORMER CONFORMED NAME: BIOLIFE SOLUTION INC
DATE OF NAME CHANGE: 20030113
FORMER COMPANY:
FORMER CONFORMED NAME: CRYOMEDICAL SCIENCES INC
DATE OF NAME CHANGE: 19920703
4
1
rdgdoc.xml
FORM 4
X0306
4
2020-02-04
0000834365
BIOLIFE SOLUTIONS INC
BLFS
0001676166
Mathers James
C/O BIOLIFE SOLUTIONS, INC.
3303 MONTE VILLA PARKWAY, SUITE 310
BOTHELL
WA
98021
1
Chief Revenue Officer
Common Stock
2020-02-04
4
M
0
2113
1.64
A
19497
D
Common Stock
2020-02-04
4
S
0
2113
14.03
D
17384
D
Employee Stock Option
1.64
2020-02-04
4
M
0
2113
0
D
2019-03-01
2021-12-20
Common Stock
2113
0
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2019.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.01 to $14.03, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The reporting person's Form 4 filed on January 23, 2019 reported a remainder of 2,613 derivative securities when in fact the remainder was 2,113 derivative securities beneficially owned by the reporting person.
/s/ James Mathers
2020-02-06